Colistin heteroresistance in Citrobacter freundii clinical isolates from Republic of Korea.

Autor: Shin JH; Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, South Korea., Shin D; Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, South Korea., Kwon KT; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea., Ko KS; Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, South Korea. Electronic address: ksko@skku.edu.
Jazyk: angličtina
Zdroj: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2024 Apr; Vol. 108 (4), pp. 116187. Date of Electronic Publication: 2024 Jan 17.
DOI: 10.1016/j.diagmicrobio.2024.116187
Abstrakt: We investigated colistin heteroresistance in Citrobacter freundii isolates from Korean hospitals. Using population analysis profiling (PAP), we detected colistin heteroresistance in 31.3% of isolates. Among these, ST217 was the most prevalent clone (58.5%), particularly within colistin-heteroresistant isolates (80.0%). Interestingly, the second most common clone, ST248, was not found in heteroresistant isolates. We identified amino acid changes in PhoQ, PmrA, and PmrB, along with mRNA overexpression in pmrB and arnD. Colistin monotherapy showed no efficacy, but a combination of colistin and ciprofloxacin successfully eradicated all five isolates, even at 0.5 × minimum inhibitory concentrations. This study underscores the high prevalence of colistin heteroresistance in C. freundii isolates, limiting the effectiveness of colistin monotherapy. Combining colistin with ciprofloxacin may offer a viable treatment option for C. freundii infections.
Competing Interests: Declaration of competing interest The authors declare that they have no competing interests.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: